Passage Bio Inc. (PASG) News
Filter PASG News Items
PASG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PASG News From Around the Web
Below are the latest news stories about PASSAGE BIO INC that investors may wish to consider to help them evaluate PASG as an investment opportunity.
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted options to purchase 10,400 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise pric |
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsOn track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 2023Expect to report initial safety and biomarker data from Dose 3 patients in global Phase 1/2 Imagine-1 clinical trial for gangliosidosis (GM1) in mid-2024Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025 PHILA |
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology ConferencePHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on |
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees. Passage Bio granted options to purchase 50,000 shares of common stock to these employees as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price |
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines ConferencePHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Monday, October 2, 2023 at 5:00 p.m ET. A live webcast of the event will be available on the Investors & Media |
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Lab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobsThis week's Lab Notes has items on a Montgomery County CDMO's expansion project, a Main Line pharmaceutical firm's licensing deal, positive study results from a Philadelphia gene therapy company and more. Here's the roundup: The Irish global contract development and manufacturing organization has started construction for its previously announced $65 million expansion project on the company’s North American headquarters campus in Souderton. The 115,000-square-foot addition, expected to be completed in 2025, will increase Alma Group's current building footprint by 50%. |
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business HighlightsReported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-20 |
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 StudyInterim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β-Gal activity and GM1 gangliosides, similar to healthy controlsDose 2 biomarker responses demonstrated durability up to 12 months after treatmentImagine-1 study participants showed initial evidence of improved survival relative to natural history dat |
Passage Bio to Participate in Upcoming Investor ConferencesPHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare ConferenceFormat: Management will participate in investor meetings Date: Tuesday, August 8, 2023Location: New York, NY Canaccord Genuity 43rd Annual Growth Conf |